Regulation

Filter

Current filters:

None

Popular Filters

2310 to 2334 of 2582 results

Germany’s IQWiG sees added benefits for Incivo

24-01-2012

In an early benefit assessment pursuant to Germany’s Act on the Reform of the Market for Medicinal…

Anti-viralsEuropeIncivekIncivoJanssenJohnson & JohnsonPharmaceuticalPricingRegulationVertex

FDA lifts hold on Insmed Arikace trial

23-01-2012

USA-based biopharma company Insmed’s (Nasdaq CM: INSM) shares leapt 33.7% to $5.08 on Friday, after…

ArikaceBiotechnologyInsmedNorth AmericaPharmaceuticalRegulationRespiratory and Pulmonary

EMA starts review of Gilenya; guidance on biosimilar interferon beta

23-01-2012

The European Medicines Agency has begun a review of the benefits and risks of Swiss drug major Novartis’…

BiotechnologyEuropeGenericsGilenyainterferon betaNeurologicalNovartisPharmaceuticalRegulation

FDA updates Tysabri label relating to anti-JCV

23-01-2012

The US Food and Drug Administration on Friday approved a product label change for Tysabri (natalizumab),…

Biogen IdecBiotechnologyElanNeurologicalNorth AmericaPharmaceuticalRegulationTysabri

EMA panel backs Novartis Cushing’s disease drug; Glivec label change

23-01-2012

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended…

EuropeGlivecNovartisOncologypasireotidePharmaceuticalRare diseasesRegulationSignifor

FDA Advisory thumbs down for Columbia and Watson product

23-01-2012

US drugmakers Columbia Laboratories (Nasdaq: CBRX) and Watson Pharmaceuticals (NYSE: WPI) confirmed on…

Columbia LaboratoriesCrinoneNorth AmericaPharmaceuticalRegulationReproductiveWatson PharmaceuticalsWomen's Health

Merck & Co gets positive CHMP opinion for Remicade in new indication

22-01-2012

US drug giant Merck & Co (NYSE: MRK) says that announced that the European Medicines Agency’s Committee…

EuropeGastro-intestinalsMerck & CoPharmaceuticalRegulationRemicade

Additional indication for Otsuka’s Abilify in Japan

22-01-2012

Japanese drugmaker Otsuka Pharmaceutical (TYO: 4768) said last week that it has received new regulatory…

AbilifyAsia-PacificNeurologicalOtsukaPharmaceuticalRegulation

Eisai gets Lunesta approval in Japan, launches Fostoin

20-01-2012

Japanese drug major Eisai (TYO: 4523) this week received approval from Japan's Ministry of Health, Labor…

Asia-PacificEisaiFostoinLunestaMarkets & MarketingNeurologicalNobelpharmaPharmaceuticalRegulation

FDA backs Gilead’s Viread for children

20-01-2012

The US Food and Drug Administration has approved US biotech firm Gilead Sciences (Nasdaq: GILD) Viread…

Anti-viralsBiotechnologyGilead SciencesNorth AmericaPharmaceuticalRegulationViread

Which of 2012's launches will be future blockbusters?

20-01-2012

A review of the year's biggest product launches - based on analyst forecasts - reveals a bumper crop…

BiotechnologyFinancialPharmaceuticalRegulation

FDA’s CRL on dapagliflozin calls for more clinical data

19-01-2012

In what comes as no surprise given a negative vote by an Food and Drug Administration advisory panel…

AstraZenecaBristol-Myers SquibbdapagliflozinDiabetesNorth AmericaPharmaceuticalRegulation

Bayer’s Xarelto OKed in Japan; promising regorafenib data

19-01-2012

Bayer Healthcare, a unit of Germany’s Bayer AG (BAY: DE), had a couple of good news item to report…

BayerCardio-vascularOncologyOnyx PharmaceuticalsPharmaceuticalregorafenibRegulationResearchXarelto

BTG’s Voraxaze gains first approval, in USA

19-01-2012

The US Food and Drug Administration has approved UK headquartered BTG International’s (LSE: BGC)…

BiotechnologyBTGNephrology and HepatologyNorth AmericaOncologyRegulationVoraxaze

Adequate global standards for registry reports required, say IQWiG staffers

17-01-2012

Different formats are available for reporting the results of clinical trials. In an article just published…

BiotechnologyEuropePharmaceuticalRegulationResearch

German pharma hails successful 2011; views AMNOG

16-01-2012

The German pharmaceutical industry can be proud of its progress last year, said Birgit Fischer, director…

EuropeMarkets & MarketingPharmaceuticalPricingRegulation

FDA completes work on three drug user fee programs

16-01-2012

The US Food and Drug Administration has completed its recommendations for three user fee programs that…

BiotechnologyFinancialGenericsNorth AmericaPharmaceuticalRegulation

“Black box” warning for Seattle Genetics’ Adcetris

16-01-2012

US biotech Seattle Genetics (Nasdaq: SGEN) saw its shares fall 5.2% to $17.49 on Friday, after the company…

AdcetrisBiotechnologyNorth AmericaOncologyRegulationSeattle Genetics

A lot of user fee issues in USA

15-01-2012

2012 has only just begun, but the US Congress, the Food and Drug Administration and several health care…

BiotechnologyGenericsNorth AmericaPharmaceuticalPoliticsRegulation

2310 to 2334 of 2582 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top